December 12, 2017 09:44 AM EST
Bioregnum
Opinion

Sanofi's R&D day pos­es some big chal­lenges as skep­tics cir­cle in wake of a Deng­vax­ia fi­as­co

Bioreg­num
The view from John Car­roll

To­mor­row the an­a­lysts that cov­er Sanofi $SNY will gath­er in Paris to hear the phar­ma gi­ant out­line …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

J&J re­ports dura­bil­i­ty da­ta for blad­der can­cer 'pret­zel' drug af­ter FDA fil­ing

Paul Stof­fels on re­tir­ing from Gala­pa­gos; Boehringer In­gel­heim switch­es up lead­er­ship

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times